
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is poised for success with its lead candidate, cadisegliatin, as an adjunctive therapy for type 1 diabetes, which has Breakthrough Therapy Designation and is currently in a Phase 3 trial expected to complete enrollment by 3Q26. Beyond the core T1D population, cadisegliatin also shows potential in adolescents and in combination with hybrid closed-loop insulin delivery systems. With a strong clinical profile and increasing relevance in the T1D landscape, vTv’s stock has potential to reach new heights, leading us to increase our price target to $57.
Bears say
vTv Therapeutics is facing multiple challenges that could impact its future growth and financial performance. These include higher than expected operating expenses, potential delays in clinical trials, and stiff competition in the T1D market. Additionally, the company is dependent on third-party suppliers and faces potential manufacturing risks. While its lead candidate, cadisegliatin, shows promise as a metabolic adjunct, it may face challenges in complementing emerging curative modalities, and its efficacy may vary in different patient populations. Overall, the company's financial outlook may be negatively impacted by these factors, leading to a negative outlook on its stock.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares